Imipenem/Cilastatin (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to bacterial lysis. Cilastatin inhibits renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby increasing its plasma concentration and prolonging its antibacterial effect.

The dosing regimen for Imipenem/Cilastatin is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and other clinical factors. Healthcare professionals should follow local guidelines and the product label.

Safety data for Imipenem/Cilastatin in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Imipenem/Cilastatin offers a broad spectrum of activity similar to other carbapenems but includes cilastatin to prevent renal degradation, resulting in higher and more stable plasma levels. This can provide a dosing advantage in patients with reduced renal function compared with carbapenems lacking a dehydropeptidase inhibitor.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted for intravenous administration, it should be used promptly according to the manufacturer’s instructions and discarded if any discoloration or particulate matter appears.

Imipenem/Cilastatin is administered intravenously by a healthcare professional. The solution is typically infused over a specified period, often 30 minutes, depending on the clinical protocol and patient tolerance. Administration should follow aseptic technique and institutional infusion guidelines.

The most serious adverse events include seizures, especially in patients with pre‑existing CNS disorders or renal impairment, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis, which can be life‑threatening and requires immediate medical attention.

Patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem should not receive this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking medications that significantly lower the seizure threshold.